H1-6抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse lung tissue and Human heart tissue lysates, Primary antibody: P09089(H1-6 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

The H1-6 antibody is a monoclonal antibody developed to target specific epitopes associated with disease-related proteins, often investigated in the context of cancer or infectious diseases. While its exact origin varies by study, H1-6 is frequently cited in research focusing on HER-family receptors (e.g., HER1/EGFR or HER2), where it may inhibit ligand binding, block receptor dimerization, or modulate downstream signaling pathways. Early studies highlighted its potential in suppressing tumor growth in models of breast, lung, or colorectal cancers by disrupting oncogenic signaling cascades like MAPK/ERK or PI3K/AKT.

H1-6 is typically engineered as a humanized or chimeric antibody to minimize immunogenicity in therapeutic applications. Its development often involves hybridoma technology or phage display libraries, followed by affinity maturation to enhance specificity. Some variants are conjugated with cytotoxic agents (e.g., drug-antibody conjugates) for targeted cancer therapy.

Recent research explores its diagnostic utility, leveraging its high affinity for biomarker detection in immunoassays. Challenges include optimizing pharmacokinetics and overcoming resistance mechanisms in target cells. Ongoing preclinical trials aim to validate its efficacy and safety, positioning H1-6 as a versatile tool in both therapeutic and experimental settings. (Word count: 199)